Q4 2024 Earnings Call Transcript March 27, 2025 Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 ...
Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback